Women’s health company Evvy announces it has raised $40 million in a Series B funding round to support further research using vaginal microbiome data. The company’s approach centers on collecting testing data related to the vaginal microbiome, which it says helps address gaps in scientific understanding relevant to women’s health.
Forbes reports that Evvy’s CEO, Priyanka Jain, discusses how the company handles sensitive biological information, including why certain genomes are kept private and how ownership of data and related materials is structured. TechCrunch reports additional deal details, including that the round is led by Catalio Capital Management.
Across the coverage, the main focus is consistent: Evvy secures new capital to expand its platform and grow its research dataset. The outlets differ mainly in emphasis—Forbes on privacy and data governance, and TechCrunch on the financing terms and lead investor—rather than on the core purpose of the funding.
